Revenue and Financial Performance - The company has not recognized any revenue through September 30, 2025, and does not expect to generate substantial product revenue in the near future [125]. - Other income for the three months ended September 30, 2025 was $0.3 million, down from $2.3 million in 2024, primarily due to reduced interest income [134]. - Other income for the nine months ended September 30, 2025 was $2.4 million, down from $8.2 million in 2024, mainly due to decreased interest income from cash and marketable securities [139]. - For the nine months ended September 30, 2025, the net cash used in operating activities was $86.6 million, primarily due to a net loss of $84.8 million [152]. - For the nine months ended September 30, 2024, net cash used in operating activities was $96.8 million, resulting from a net loss of $94.2 million [153]. Cash and Funding - A cash contribution of $275.0 million was received from the Former Parent in the fourth quarter of 2023 at the time of the Separation [113]. - The company received a cash contribution of $275.0 million from the Former Parent on November 14, 2023, as part of the Separation [141]. - The company expects to fund its operating expenses and capital requirements for at least twelve months following September 30, 2025, based on current cash and cash equivalents [142]. - The cash, cash equivalents, and restricted cash at the end of the period were $60.6 million, down from $271.1 million at the beginning of the period [151]. - The company has entered into an "at-the-market" offering agreement with Jefferies LLC for up to $75.0 million, with no shares sold under this agreement as of September 30, 2025 [150]. Research and Development - R&D expenses for the three months ended September 30, 2025 decreased by $4.3 million to $27.6 million compared to $31.9 million in 2024, primarily due to the cessation of all R&D activities following restructuring [132]. - Total R&D expenses for the nine months ended September 30, 2025 were $46.4 million, a decrease of $35.6 million from $82.0 million in 2024, attributed to the wind-down of R&D activities [136]. - The company has ceased all remaining development activities on its preclinical programs as of June 3, 2025 [104]. - The ARTISTRY-7 trial of nemvaleukin did not achieve its primary endpoint, leading to the cessation of its development for platinum-resistant ovarian cancer [104]. Workforce and Restructuring - The company announced a reduction in workforce by approximately 90% following the discontinuation of clinical development of nemvaleukin [119]. - Restructuring and impairment charges for the nine months ended September 30, 2025 totaled $17.5 million, including $9.5 million in employee-related costs and $5.5 million in impairment charges [138]. Corporate Structure and Compliance - The company operates as an independent, publicly traded company under the symbol "MURA" since November 16, 2023, following the Separation [114]. - The company is prohibited from taking actions that would prevent the Separation from qualifying as tax-free for U.S. federal income tax purposes for a four-year period [121]. - The company has not made significant changes to its critical accounting policies or estimates since the last reporting period [163]. Lease and Other Financial Obligations - The remaining contractual operating lease liability associated with the Winter Street Lease was $3.5 million as of September 30, 2025 [161]. - The company entered into sub-leases that are expected to generate a total annualized fixed base rent of $1.2 million from August 2024 to April 2026 [159][160]. - Net cash provided by financing activities was $28 thousand for the nine months ended September 30, 2025, primarily from the issuance of ordinary shares under employee share plans [156]. - The company had $9.8 million in cash used by working capital changes for the nine months ended September 30, 2025 [152].

Revenue Performance - Total revenue for Q3 2025 was $70 million, down 18% from $85 million in Q3 2024[12] - Total revenue for Q3 2025 was $70.445 million, a decrease of 16.6% compared to $84.512 million in Q3 2024[30] - Product sales in Q3 2025 were $13.442 million, down from $41.528 million in Q3 2024, representing a decline of 67.6%[30] - Licensing, royalties, and other revenue increased to $57.003 million in Q3 2025 from $42.984 million in Q3 2024, a growth of 32.5%[30] - Full Year 2025 revenue guidance is projected between $1,040 million and $1,060 million[18] Expenses and Losses - Research and development (R&D) expenses for Q3 2025 were $98 million, up from $87 million in Q3 2024[16] - Selling, general, and administrative (SG&A) expenses decreased by 55% to $32 million in Q3 2025, compared to $71 million in Q3 2024[16] - Total expenses for Q3 2025 were $248.463 million, up from $218.530 million in Q3 2024, an increase of 13.7%[30] - Net loss for Q3 2025 was $202 million, compared to a net loss of $121 million in Q3 2024[16] - Net loss for Q3 2025 was $202.379 million, compared to a net loss of $121.300 million in Q3 2024, reflecting a worsening of 66.9%[30] Cash and Assets - Cash and cash equivalents were $778 million as of September 30, 2025, down from $938 million as of December 31, 2024[16] - Cash and cash equivalents decreased to $268.023 million as of September 30, 2025, from $530.230 million at the end of 2024[32] - Total assets decreased to $1.179 billion as of September 30, 2025, down from $1.560 billion at the end of 2024[32] - Working capital improved to $544.721 million as of September 30, 2025, compared to a deficit of $25.474 million at the end of 2024[32] - The company reported an impairment of assets held for sale amounting to $97.038 million in Q3 2025[30] Partnerships and Future Outlook - Sanofi partnership milestones achieved year-to-date totaled $225 million, including $50 million earned in Q4 2025[4] - The company expects approximately $230 million in future cost savings from Maryland site consolidation transactions[4] - The FDA approved the Nuvaxovid 2025-2026 Formula for COVID-19 prevention in high-risk individuals in August 2025[8] - Novavax is focusing on expanding its clinical pipeline and expects to advance its product candidates, including new Matrix formulations[29] Nuvaxovid Sales - Nuvaxovid sales were $0 million in Q3 2025, a decrease of $38 million compared to $38 million in Q3 2024[9]

Financial Performance - LSI reported fiscal 2026 first quarter net sales of $157.3 million, an increase of 14% year-over-year, with organic growth of 7%[3][6][28] - Net income for the first quarter was $7.3 million, or $0.23 per diluted share, compared to $6.7 million, or $0.22 per diluted share in the prior year, representing a 9% increase in net income[3][6][28] - Adjusted EBITDA for the first quarter was $15.6 million, reflecting a 17% increase year-over-year, with an adjusted EBITDA margin of 10.0%[4][6] - Net sales for Q3 2025 reached $157,249,000, a 14% increase from $138,095,000 in Q3 2024[33] - Adjusted operating income for Q3 2025 was $14,025,000, reflecting an 18% growth compared to $11,898,000 in Q3 2024[33] - Adjusted net income for Q3 2025 was $9,731,000, a 22% increase from $7,981,000 in Q3 2024[34] - Diluted earnings per share (EPS) as adjusted rose to $0.31 in Q3 2025, up 19% from $0.26 in Q3 2024[34] - EBITDA for Q3 2025 was $14,172,000, representing a 17% increase from $12,071,000 in Q3 2024[36] - Organic net sales for Q3 2025 were $148,330,000, a 7% increase from $138,095,000 in Q3 2024[37] Segment Performance - The Lighting segment achieved 18% year-over-year sales growth, while the Display Solutions segment saw an 11% increase in sales[15][28] - The Lighting Segment reported sales of $69,053,000, an 18% increase from $58,437,000 in Q1 2025[37] - Total Display Solutions sales increased by 11% to $88,196,000 in Q3 2025, compared to $79,658,000 in Q3 2024[37] Cash Flow and Debt Management - The company expects to return to positive cash flow during the fiscal second quarter after increased working capital investments impacted free cash generation in the first quarter[5] - Free cash flow for Q3 2025 was negative $292,000, a significant decline from positive $11,087,000 in Q3 2024, indicating a 103% decrease[36] - LSI's ratio of net debt to trailing twelve-month adjusted EBITDA was 0.8x, indicating a strong balance sheet[5][6] - The net debt to adjusted EBITDA ratio remained stable at 0.8 for both September 30, 2025, and 2024[36] Strategic Initiatives - LSI amended and extended its credit facility, increasing availability from $75 million to $125 million, ensuring ample liquidity for strategic growth initiatives[17] - LSI's acquisition of Canada's Best Holdings in March 2025 contributed to improved demand and sales growth across its segments[8][10] - The company continues to focus on high-value verticals, with ongoing development activity in the refueling/c-store and grocery verticals, indicating a positive long-term outlook[11][12][18] Dividend Information - The company declared a quarterly cash dividend of $0.05 per share, payable on November 25, 2025, with an indicated annual cash dividend rate of $0.20 per share[7][30]

Financial Performance - UroGen reported total revenues of $27.5 million for Q3 2025, with JELMYTO generating $25.7 million, reflecting a year-over-year growth of approximately 13%[12][8] - ZUSDURI achieved net product revenue of $1.8 million in its first quarter on the market, with preliminary demand revenue for October 2025 estimated at $4.5 million, indicating accelerating growth[12][6] - UroGen reported a net loss of $33.3 million or ($0.69) per share in Q3 2025, compared to a net loss of $23.7 million or ($0.51) per share in Q3 2024[18][26] - The company expects full-year 2025 net product revenues for JELMYTO to be in the range of $94 to $98 million, implying a growth rate of approximately 8% to 12% over 2024[21] Research and Development - R&D expenses for Q3 2025 were $14.0 million, an increase from $11.4 million in Q3 2024, primarily due to costs associated with the UTOPIA trial[13] - The three-month complete response rate for UGN-103 was reported at 77.8% in the Phase 3 UTOPIA trial, consistent with previous results, and the FDA agreed to the NDA submission plan[16][6] - UroGen has made the strategic decision to discontinue the development of UGN-301 after its Phase 1 study, as it did not meet internal benchmarks for advancement[16] - UroGen plans to submit a New Drug Application (NDA) for UGN-103 and is conducting ongoing clinical trials for UGN-104 and UGN-501[46] Commercial Activities - SG&A expenses rose to $37.6 million in Q3 2025, compared to $28.9 million in the same period in 2024, driven by ZUSDURI commercial launch activities[14] - As of October 31, 2025, UroGen reported 592 activated sites of care and 54 unique prescribers for ZUSDURI since its launch on July 1, 2025[7] - Preliminary demand revenue estimate for ZUSDURI in October indicates accelerating commercial uptake and growing physician adoption[46] Product Information - ZUSDURI (mitomycin) is approved for treating adults with recurrent low-grade intermediate risk non-muscle invasive bladder cancer (LG-IR-NMIBC) after ineffective prior surgery[28] - JELMYTO (mitomycin) is indicated for adult patients with low-grade upper tract urothelial cancer (LG-UTUC) and is administered via a ureteral catheter or nephrostomy tube[37] - UroGen's proprietary RTGel technology allows for sustained release of medication, improving therapeutic profiles and potentially enhancing treatment effectiveness[45] - UroGen's sustained release technology aims to improve local delivery of complex immunotherapies, enhancing treatment options[46] Safety and Side Effects - The most common side effects of ZUSDURI include increased blood creatinine levels and urinary tract infections[35] - JELMYTO may cause serious side effects, including ureteric obstruction and bone marrow problems, necessitating blood tests prior to treatment[47] Company Overview - UroGen is headquartered in Princeton, NJ, with operations in Israel, focusing on innovative solutions for urothelial and specialty cancers[45]

Financial Performance - Net income for Q3 2025 was $16.3 million, or $0.96 per diluted common share, up from $11.2 million, or $0.66 per diluted common share in Q3 2024, representing a 45.5% increase in net income year-over-year [113]. - For the nine months ended September 30, 2025, net income was $43.2 million, or $2.55 per diluted common share, compared to $33.2 million, or $1.96 per diluted common share for the same period in 2024, reflecting a 30.2% increase [114]. - Return on average equity (annualized) for Q3 2025 was 13.89%, compared to 10.36% in Q3 2024, indicating improved profitability [113]. - Return on average assets (annualized) for Q3 2025 was 1.47%, up from 1.05% in Q3 2024, showing enhanced asset efficiency [113]. Net Interest Income - Net interest income is the principal source of the Company's net income, driven by the difference between interest income and interest expense [115]. - The Company monitors yields on loans and interest-earning assets, costs of deposits, net interest spread, and net interest margin to evaluate net interest income [115]. - For the three months ended September 30, 2025, net interest income increased to $43.3 million, up 15.4% from $37.5 million in the same period of 2024 [122]. - Net interest income for the nine months ended September 30, 2025 was $124.0 million, an increase of $15.5 million, or 14.3%, compared to the same period in 2024 [124]. - The net interest margin for the three months ended September 30, 2025, was 4.05%, compared to 3.65% for the same period in 2024 [123]. - Net interest margin and net interest spread improved to 3.98% and 3.02%, respectively, for the nine months ended September 30, 2025, compared to 3.61% and 2.53% for the same period in 2024 [125]. Asset and Deposit Growth - Total assets of the company reached $4.41 billion as of September 30, 2025, compared to $4.26 billion in 2024 [122]. - Total deposits increased by $260.3 million, or 7.2%, to $3.88 billion at September 30, 2025, compared to $3.62 billion at December 31, 2024 [148]. - Noninterest-bearing demand deposits increased by $34.1 million for the three months ended September 30, 2025, compared to the same period in 2024 [122]. - Total average loans outstanding during the three months ended September 30, 2025, were $3,093.5 million, compared to $3,069.9 million for the same period in 2024 [174]. Credit Quality and Risk Management - The Company faces risks including economic growth rates, competition for deposits, and inflationary pressures that could impact future performance [107]. - The Company emphasizes the importance of maintaining effective internal controls and managing credit risk to safeguard financial results [112]. - The provision for credit losses for the nine months ended September 30, 2025 was $3.4 million, an increase of $300 thousand, or 9.7%, compared to $3.1 million for the same period in 2024 [128]. - The company continues to monitor credit quality due to ongoing economic uncertainties, including elevated interest rates and inflationary pressures [172]. - The allowance for credit losses (ACL) is evaluated quarterly, considering historical experience and current economic conditions [241]. Capital and Equity - As of September 30, 2025, total stockholders' equity increased to $477.8 million, up $38.9 million or 8.9% from $438.9 million as of December 31, 2024 [216]. - The Company is currently meeting all capital adequacy requirements and is classified as "well capitalized" under regulatory standards [218]. - Total capital to risk-weighted assets ratio was 17.34% as of September 30, 2025, compared to 17.86% as of December 31, 2024 [220]. - Tier 1 capital to risk-weighted assets ratio increased to 15.69% as of September 30, 2025, from 14.80% as of December 31, 2024 [220]. Interest Rate Risk Management - The ALCO Committee manages interest rate risk, considering factors such as earnings impact, regional economies, and liquidity [227]. - The company employs interest rate risk simulation models to assess the sensitivity of net interest income and fair value of equity [228]. - Under the static model, a 100 basis point shift in interest rates could lead to a maximum decline of 7.5% in estimated net interest income at risk for the subsequent one-year period [229]. - As of September 30, 2025, a 300 basis point increase in interest rates would result in a simulated decrease of 2.48% in net interest income [230].

Exhibit 99.1 Outlook Guidance for the fiscal year ending June 30, 2026 has been increased and now includes the Curtis acquisition: • Sales were a record $5.1 billion; organic sales growth was 5% • Net income was $808 million, an increase of 16%, or $927 million adjusted, an increase of 14% • EPS were $6.29, an increase of 18%, or a record $7.22 adjusted, an increase of 16% • Segment operating margin was 24.2%, an increase of 160 bps, or 27.4% adjusted, an increase of 170 bps • Cash flow from operations was ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-39487 Silence Therapeutics plc (Exact name of registrant as specified in its charter) | England and Wales | ...

Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance PITTSBURGH – November 6, 2025 – Viatris Inc. (Nasdaq: VTRS) today reported strong third quarter 2025 financial results and updated full-year financial guidance. Executive Commentary "We delivered another strong quarter by staying focused on our 2025 strategic priorities," said Scott A. Smith, Chief Executive Officer, Viatris. "Our performance this quarter reflects the continued strength of our execution across markets. We are adv ...

Revenue Growth - Backblaze reported a revenue growth of 28% for B2 Cloud Storage in the current quarter compared to the same period last year[128]. - The annual recurring revenue (ARR) for B2 Cloud Storage increased to $81.8 million as of September 30, 2025, up from $64.9 million in the previous year, representing a growth of 26%[144]. - Backblaze's total annual recurring revenue reached $147.2 million as of September 30, 2025, compared to $130.5 million in the previous year[144]. - Revenue for the three months ended September 30, 2025, was $37,162 thousand, a 14% increase from $32,589 thousand in the same period of 2024[168]. Customer Retention - The net revenue retention rate for B2 Cloud Storage was 110% as of September 30, 2025, down from 128% in the previous year, attributed to the impact of a price increase announced in October 2023[145]. - Backblaze's gross customer retention rate remained stable at 89% for B2 Cloud Storage and 90% for Computer Backup as of September 30, 2025[144]. Product Development - The company launched B2 Overdrive, a premium cloud storage solution, in April 2025 to cater to data-intensive workloads[139]. - The company is focusing on expanding revenue within existing customers through new features and enhanced customer success programs[136]. - Backblaze's direct sales activities are increasingly contributing to the acquisition of larger customers as the company moves up-market[126]. Financial Performance - Gross margin improved to 62% for the three months ended September 30, 2025, compared to 55% for the same period in 2024, primarily due to a decrease in depreciation expense[174]. - The net loss for the three months ended September 30, 2025, was $3,778 thousand, compared to a net loss of $12,753 thousand in the same period of 2024[168]. - Adjusted gross profit increased to $29,359 thousand for the three months ended September 30, 2025, compared to $25,469 thousand for the same period in 2024, with an adjusted gross margin of 79%[186]. - Adjusted EBITDA increased to $8,387 thousand for the three months ended September 30, 2025, compared to $3,749 thousand for the same period in 2024, with an adjusted EBITDA margin of 23%[189]. Expenses - Research and development expenses for the three months ended September 30, 2025, were $11,235 thousand, representing 30% of total revenue[168]. - Sales and marketing expenses for the three months ended September 30, 2025, were $8,996 thousand, accounting for 24% of total revenue[168]. - The company expects operating expenses, excluding depreciation and stock-based compensation, to remain flat in 2025 compared to the prior year[158]. - Investment in research and development is anticipated to increase in absolute dollars as the company focuses on enhancing cloud service offerings[160]. Cash Flow and Investments - Net cash provided by operating activities was $14,231 thousand for the nine months ended September 30, 2025, compared to $10,272 thousand for the same period in 2024[195]. - Adjusted free cash flow was $(9,485) thousand for the nine months ended September 30, 2025, improving from $(15,603) thousand for the same period in 2024, with an adjusted free cash flow margin of (9%) compared to (17%) in 2024[195]. - The company incurred cash used in investing activities of $22.2 million for the nine months ended September 30, 2025, up from $11.9 million in the same period of 2024[220]. Debt and Financing - The company has $20.0 million available under a senior secured revolving credit facility, with $2.5 million outstanding as of September 30, 2025, and an interest rate of 7.51%[204]. - The company amended its credit agreement in August 2025 to permit share repurchases, allowing up to $10.0 million to be excluded from covenant restrictions[206]. - The company was in compliance with the covenants under the credit agreement as of September 30, 2025, which includes a minimum liquidity requirement of $10.0 million[207]. Market and Currency Risks - The company has minimal foreign currency risk as most sales and operating expenses are denominated in U.S. dollars[230]. - Future international sales increases may expose the company to foreign currency exchange rate fluctuations[230]. - The company may consider using derivatives or other financial instruments in the future to hedge foreign currency exchange risk[230].

Product Development and Pipeline - The company reported a significant focus on expanding its product pipeline, particularly in radiopharmaceutical oncology and precision diagnostics, with a commitment to improving patient outcomes [175]. - The FDA has set a PDUFA target action date of March 29, 2026, for LNTH-2501, a diagnostic kit for Gallium-68 edotreotide Injection, aimed at neuroendocrine tumors [181]. - The company announced the acceptance of its New Drug Application for MK-6240, with a PDUFA target action date of August 13, 2026, following successful pivotal studies [182]. - The company aims to optimize the manufacturing process of its F-18 PSMA PET imaging agent, potentially increasing batch size by approximately 50% [184]. - The company plans to submit an NDA for NAV-4694 in 2026, following an upfront payment of $32.9 million for the investigational asset [223]. Acquisitions and Partnerships - An exclusive licensing agreement was established with GE HealthCare for the development and commercialization of piflufolastat F-18 in Japan, with upfront fees and royalties based on sales [183]. - The acquisition of Life Molecular Imaging Ltd. was completed for an upfront payment of $355.2 million, with potential additional payments of up to $400 million based on milestones [186][187]. - The company acquired Evergreen Theragnostics, Inc. for an upfront payment of $276.4 million, with potential additional payments of up to $727.5 million based on milestone achievements [191][192]. - The company acquired NAV-4694, an investigational PET imaging agent for Alzheimer's disease, for an upfront payment of $32.9 million, with additional payments contingent on regulatory milestones [194][195]. - The company entered into an agreement with Radiopharm for preclinical assets, paying an upfront amount of $2.0 million, and assumed related milestone and royalty obligations [197][198]. - The company entered into a definitive agreement to sell its SPECT business to SHINE, allowing a focus on growing its PET radiodiagnostics portfolio [193]. Financial Performance - The company reported revenues of $384.0 million for the three months ended September 30, 2025, representing a 1.4% increase from $378.7 million in the same period of 2024 [230]. - Cost of goods sold increased by 18.3% to $161.6 million for the three months ended September 30, 2025, compared to $136.6 million in the prior year [230]. - Gross profit decreased by 8.2% to $222.4 million for the three months ended September 30, 2025, down from $242.1 million in 2024 [230]. - Operating expenses rose by 64.9% to $178.8 million for the three months ended September 30, 2025, compared to $108.4 million in the same period of 2024 [230]. - Net income for the three months ended September 30, 2025, was $27.8 million, a decrease of 78.8% from $131.1 million in 2024 [230]. - Revenues for the three months ended September 30, 2025, increased by $5.3 million (1.4%) to $384.0 million compared to the same period in 2024, primarily driven by sales of Neuraceq and increased DEFINITY sales volume [232]. - For the nine months ended September 30, 2025, total revenues decreased by $8.0 million (0.7%) to $1,134.8 million, mainly due to a decrease in the net sales price of PYLARIFY and a decrease in TechneLite sales volume [233]. Expenses and Costs - The company reported a significant increase in general and administrative expenses, which rose by 102.1% to $81.9 million for the three months ended September 30, 2025 [230]. - Sales and marketing expenses increased by $5.1 million for the three months ended September 30, 2025, due to increased sales costs related to Neuraceq and contract manufacturing services [239]. - R&D expenses increased by $23.9 million for the three months ended September 30, 2025, primarily due to the impact of acquisitions and investments in late-stage assets [244]. - General and administrative expenses rose by $41.4 million and $69.4 million for the three and nine months ended September 30, 2025, respectively, driven by the impact of acquisitions and increased professional fees [242]. Cash Flow and Financing - Net cash provided by operating activities was $300.0 million for the nine months ended September 30, 2025, a decrease from $387.0 million in the same period of 2024 [251]. - Net cash used in investing activities was $615.7 million for the nine months ended September 30, 2025, significantly higher than $219.4 million in the same period of 2024, primarily due to acquisitions [254]. - Net cash used in financing activities for the nine months ended September 30, 2025, was approximately $200.0 million, primarily due to stock repurchases [256]. - The company issued $575.0 million in Convertible Senior Notes due 2027, with net proceeds of approximately $557.8 million [262]. - The company amended its revolving credit facility, increasing the commitment from $350.0 million to $750.0 million and extending the maturity date to December 19, 2029 [206][207]. Market Position and Future Outlook - PYLARIFY, an F-18 PET imaging agent, was launched in June 2021 and is expected to maintain its position as the most utilized PSMA PET imaging agent despite increasing competition [208][209]. - DEFINITY is expected to maintain at least an 80% market share in the U.S. for ultrasound enhancing agents in echocardiography procedures [212][213]. - Neuraceq revenue growth will depend on increased adoption of beta-amyloid PET and anti-amyloid therapeutics, along with expanded geographical access and enhanced manufacturing capacity [214]. - Future capital requirements will depend on product sales, pricing environment, and ongoing commercialization costs [266]. - The company may need to finance cash needs through public or private equity offerings or debt financings if capital resources become insufficient [268]. Leadership and Strategic Focus - The leadership transition plan includes the retirement of the CEO by December 31, 2025, with an interim CEO appointed to lead the company during the search for a new CEO [179][180]. - The strategic focus includes expanding into new markets and enhancing development capabilities through acquisitions and partnerships [178]. - The company is focused on expanding its Strategic Partnerships and Other Revenue category, particularly in radiopharmaceuticals for oncology and neurology [215].